Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.
Age>18 years and <70 years old (including threshold), gender not limited；
Grade II to IV gastrointestinal involvement acute graft-versus-host disease(aGVHD)；
Subjects with Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)；
Failed to second-line aGVHD treatment;
Subjects have lung disease, and investigators have determined that they are not suitable for the study;
Subjects with severe hepatic vein occlusion disease or sinus vein occlusion syndrome;
Subjects with signs/symptoms of chronic GVHD;
Subjects who are clinically assessed by the investigator could not be ruled out as having diarrhea caused by cytomegalovirus (CMV) enteritis, transplant related thrombotic microvascular disease (TA-TMA), or digestive tract infection;